Prof. Dr. Falk Nimmerjahn

Lehrstuhl für Genetik

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. (2015) Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, et al. Journal article Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. (2015) Luenemann JD, Nimmerjahn F, Dalakas MC Journal article, Review article Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. (2015) Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, De La Torre JC, Nimmerjahn F, Brooks DG Journal article No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer. (2015) Lux A, Nimmerjahn F Journal article Three blocks are not enough-Blocking of the murine IgG receptor FcγRIV is crucial for proper characterization of cells by FACS analysis (2015) Biburger M, Trenkwald I, Nimmerjahn F Journal article, Note bIgG time for large eaters: Monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression (2015) Gordan S, Biburger M, Nimmerjahn F Journal article, Review article Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. (2014) Kao D, Böhm S, Nimmerjahn F Journal article, Review article Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation. (2014) Schwab I, Nimmerjahn F Journal article, Review article Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. (2014) Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Koehl J, Goletz S, et al. Journal article Targeting B cells and autoantibodies in the therapy of autoimmune diseases. (2014) Kao D, Lux A, Schwab I, Nimmerjahn F Journal article, Review article